Indaptus Therapeutics

Summary

History

Mission

Vision

References

Summary

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is based in New York, New York.

History

Indaptus was founded in 2017 by a team of scientists, engineers, and healthcare professionals committed to advancing gene therapy treatments. Our team has decades of experience in the biopharmaceutical industry and has actively led the development of many of today’s leading gene therapy products.

Mission

Our mission is to transform lives by creating innovative, curative, and cost-effective gene therapy treatments that address unmet therapeutic needs.

Vision

Our vision is to revolutionize how diseases are treated, enabling more people to lead healthier, longer lives.

References

https://in.investing.com/equities/intec-pharma

https://finance.yahoo.com/quote/INDP/profile?p=INDP

https://www.crunchbase.com/organization/indaptus-therapeutics

https://indaptusrx.com

Leadership team

Mr. Jeffrey A. Meckler (CEO & Director)

Dr. Michael J. Newman Ph.D. (Founder, Chief Scientific Officer & Director)